Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial - Université Paris-Est-Créteil-Val-de-Marne Access content directly
Journal Articles Lancet Oncology Year : 2022

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Nicolas Doumerc
  • Function : Author
Philippe Paparel
  • Function : Author
Jean-Christophe Bernhard
  • Function : Author
Karim Bensalah
  • Function : Author
Thibault Tricard
  • Function : Author
Thibaut Waeckel
  • Function : Author
Géraldine Pignot
  • Function : Author
Elena Braychenko
  • Function : Author
Stefano Caruso
  • Function : Author
Cheng-Ming Sun
  • Function : Author
Virginie Verkarre
  • Function : Author
Guillaume Lacroix
  • Function : Author
Marco Moreira
  • Function : Author
Maxime Meylan
  • Function : Author
Antoine Bougouïn
  • Function : Author
Letuan Phan
  • Function : Author
Christelle Thibault-Carpentier
  • Function : Author
Jessica Zucman-Rossi
  • Function : Author
Wolf Herman Fridman
  • Function : Author
Catherine Sautès-Fridman
  • Function : Author
Stéphane Oudard
  • Function : Author

Dates and versions

hal-04242379 , version 1 (14-10-2023)

Identifiers

Cite

Yann-Alexandre Vano, Réza Elaidi, Mostefa Bennamoun, Christine Chevreau, Delphine Borchiellini, et al.. Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncology, 2022, 23 (5), pp.612-624. ⟨10.1016/S1470-2045(22)00128-0⟩. ⟨hal-04242379⟩
45 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More